News Archives

News Archives

Avivagen Selects Meyenberg International Group to Spearhead Expansion Efforts in Central and South America

Ottawa, ON / February 24, 2021 / – Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce that it has chosen Meyenberg International …Read More

Avivagen Announces the Publication of its New Zealand OxC-betaTM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis

Ottawa, ON / Business Wire / February 18, 2021 / – Avivagen Inc.  (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce that a paper “Evaluation …Read More

Avivagen Inc. Announces Closing Of $7.5 Million Bought Deal Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.   OTTAWA, ON / Business Wire/– February 16, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support …Read More

Avivagen Inc. Announces Filing Of Final Short Form Prospectus For Previously Announced $7.5 Million Bought Deal Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, ON / Business Wire/– February 9, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune …Read More

Mimi’s Rock Corp. and Avivagen Announce Launch of Dr. Tobias Beta Blend on Amazon.com

Ottawa, ON / Business Wire/ February 1, 2021 / – Mimi’s Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), are pleased to announce the launch of Dr. Tobias Beta Blend available today through Amazon.com and DrTobias.com. An exclusive formula featuring a Beta-Carotene Norisporenoid Blend and Vitamin A, Beta Blend provides advanced immune support while …Read More

Avivagen Inc. Announces Upsize To Previously Announced Bought Deal Unit Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. OTTAWA, ON / Business Wire/– January 27, 2021 – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune …Read More